Alk-Abello AS (fra:4AJ0) Share Price

Company Profile

Business description
Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.
Contact
Boge Alle 6-8
HorsholmDK-2970
DNK
T: +45 45747576
E: [email protected]
https://www.alk.net
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
2,764

Recommended

The stocks of these high-quality companies with large market capitalizations look undervalued today.

Margaret Giles | 02 February 2026

Prices of these shares exceed our Fair Value Estimate by more than double.

Morningstar | 02 February 2026

Compounders tend to deliver steadier, more durable profit growth across full cycles, making them better suited for long-term investors.

Robert M. Almeida | 02 February 2026

Index	Last price	Change	% Change
All Ordinaries	9,068.80	42.20	-0.46%
CAC 40	8,181.88	55.35	0.68%
DAX 40	24,753.03	214.22	0.87%
Dow JONES (US)	49,112.97	220.50	0.45%
FTSE 100	10,321.46	97.92	0.96%
HKSE	26,775.57	611.54	-2.23%
NASDAQ	23,507.95	46.13	0.20%
Nikkei 225	52,655.18	667.67	-1.25%
NZX 50 Index	13,412.44	10.74	-0.08%
S&P 500	6,953.59	14.56	0.21%
S&P/ASX 200	8,778.60	42.50	-0.48%
SSE Composite Index	4,015.75	102.20	-2.48%